Advanced and/or Metastatic Solid Tumours Clinical Trial
Official title:
A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours
This is a phase I trial of nimotuzumab that will be conducted in patients with advanced incurable solid tumors. This is a dose-seeking study to determine the maximum tolerated and recommended phase II doses of nimotuzumab that can be safely given to patients with advanced and/or metastatic solid tumors.
This is an open-label, dose-escalating, phase I trial of nimotuzumab in patients with advanced incurable solid tumors. The objective of this study is to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of nimotuzumab that can be given in a weekly schedule in patients with advanced and/or metastatic solid tumor cancer. This study will also examine the safety, pharmacodynamics and preliminary efficacy of nimotuzumab in this patient population. ;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04839991 -
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
|
Phase 1 | |
| Active, not recruiting |
NCT05836623 -
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
|
Phase 1 |